FDA Approved: OZURDEX — Supplemental Application (Allergan, Inc.)

View source ↗

Summary

FDA approved a supplemental application for OZURDEX (dexamethasone) from Allergan, Inc., likely resulting in changes to the product labeling.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetic Macular Edema
• Noninfectious Posterior Uveitis
• Retinal Vein Occlusion

Drugs mentioned

• Ozurdex (dexamethasone intravitreal implant)

Snippet

SUPPL AP for OZURDEX (DEXAMETHASONE)